SoFi CEO enters prepaid forward contract on 1.5 million shares
Marshall Robert J. Jr., the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc. (NASDAQ:LNTH), executed a sale of 10,000 shares of the company’s common stock. The transaction, which took place on March 17, 2025, was completed at a price of $100.52 per share, amounting to a total of $1,005,200. Following this sale, Marshall retains ownership of 113,860 shares. The company, currently valued at $7.1 billion, has demonstrated strong financial performance with a 77% return over the past year and maintains an "EXCELLENT" financial health rating according to InvestingPro analysis.
This transaction was conducted under a Rule 10b5-1 trading plan, which Marshall adopted on August 12, 2024. These plans allow company insiders to set up a predetermined schedule for selling stocks, helping to avoid potential accusations of insider trading. With analysts maintaining a strong buy consensus and InvestingPro data showing the stock trading below its Fair Value, investors can access comprehensive analysis and 12 additional exclusive ProTips through the detailed Pro Research Report available for this high-performing healthcare company.
In other recent news, Lantheus Holdings reported its fourth-quarter 2024 earnings, exceeding analyst expectations with earnings per share of $1.59 and revenue of $391.1 million, surpassing the forecast of $377.24 million. The company noted a robust performance driven by its flagship product, Polarify, which contributed significantly to revenue growth. For the full year, Lantheus achieved a revenue increase of 18.3%, reaching $1.534 billion. Looking ahead, Lantheus has set a revenue guidance of $1.545 billion to $1.610 billion for 2025. Additionally, Mizuho (NYSE:MFG) Securities adjusted its financial outlook for Lantheus, reducing the price target from $150.00 to $140.00 while maintaining an Outperform rating. This adjustment followed Lantheus’ earnings report, which exceeded expectations by $15 million and $0.05 per share. Furthermore, the company’s future growth prospects include pending acquisitions of Life Molecular Imaging and Evergreen Medical (TASE:BLWV) Services, which are expected to close in the second half of the year. These transactions are anticipated to enhance Lantheus’ capabilities in Alzheimer’s diagnostics and oncology therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.